Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078337 · ClinicalTrials.gov registry record
T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis
A clinical trial of Leukemia, Lymphocytic, Acute, sponsored by Stanford University.
- Completed
- Registry status
- 15
- Enrollment target
- 1
- Study location
NCT01078337 is a study of Leukemia, Lymphocytic, Acute that has completed, run by Stanford University. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01078337, a study of Leukemia, Lymphocytic, Acute, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).
Conditions Studied
Interventions
- PROCEDURE bone marrow aspiration
- PROCEDURE peripheral blood sampling
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2002-11 |
| Est. Completion | 2007-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078337
The ClinicalTrials.gov registry entry for NCT01078337 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Lymphocytic, Acute appearing as the primary indexed condition, and to 2 interventions - of which bone marrow aspiration is the first listed.
NCT01078337 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01078337 about?
NCT01078337 is a clinical study titled "T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis". To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).
What is the current status of trial NCT01078337?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2002-11. Estimated completion is 2007-10.
What conditions does trial NCT01078337 study?
This clinical trial studies the following conditions: Leukemia, Lymphocytic, Acute.
What interventions are being tested in trial NCT01078337?
The interventions under investigation include: bone marrow aspiration (PROCEDURE), peripheral blood sampling (PROCEDURE).
Who is sponsoring clinical trial NCT01078337?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01078337 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Lymphocytic, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.